Nikolas I Wada1, Jay H Bream2, Otoniel Martínez-Maza3, Bernard Macatangay4, Shannon R Galvin5, Joseph B Margolick2, Lisa P Jacobson1. 1. Department of Epidemiology. 2. Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Department of University of California, Los Angeles AIDS Institute. 4. Department of Medicine, University of Pittsburgh, Pennsylvania. 5. Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV)-induced inflammation and immune activation persist after initiation of combination antiretroviral therapy (cART) and HIV suppression and may contribute to mortality risks that exceed those in HIV-uninfected populations, though associations are unclear. METHODS: In the prospective Multicenter AIDS Cohort Study, comprising men who have sex with men from Baltimore, Chicago, Los Angeles, and Pittsburgh, concentrations of 24 biomarkers of inflammation and immune activation were measured in stored serum from HIV-positive men obtained after cART-induced HIV suppression between 1996 and 2009. The outcome was nonaccidental death, with follow-up until 2014. We used Cox proportional hazards models to test whether biomarker concentrations predict time from HIV suppression to death and adjusted for multiple tests. Exploratory factor analysis (EFA) was employed to identify groupings of biomarkers that predict mortality risk. RESULTS: Of 670 men followed up from HIV suppression, 54 died by the end of 2013. After adjustment for age, CD4(+) cell count, hepatitis B or C virus infection, and smoking, concentrations in the highest quartile of 4 biomarkers were significantly associated with mortality risk after controlling the false discovery rate at 5%: interleukin (IL) 6 (hazard ratio, 3.54; 95% confidence interval, 2.06-6.10), soluble IL 2Rα (3.29, 1.85-5.85), soluble CD14 (2.67, 1.55-4.61), and chemokine (CXC motif) ligand 13 (CXCL13; 2.26; 1.29-3.95). EFA yielded 2 biomarker groupings that were independent predictors of mortality risk. CONCLUSIONS: Despite having undetectable HIV RNA levels during cART, men with higher concentrations of several biomarkers (particularly IL 6, soluble IL 2Rα, soluble CD14, and CXCL13) had higher hazards of long-term mortality. Correlations observed among biomarker concentrations may represent underlying inflammatory processes that contribute to mortality risk.
BACKGROUND:Human immunodeficiency virus (HIV)-induced inflammation and immune activation persist after initiation of combination antiretroviral therapy (cART) and HIV suppression and may contribute to mortality risks that exceed those in HIV-uninfected populations, though associations are unclear. METHODS: In the prospective Multicenter AIDS Cohort Study, comprising men who have sex with men from Baltimore, Chicago, Los Angeles, and Pittsburgh, concentrations of 24 biomarkers of inflammation and immune activation were measured in stored serum from HIV-positive men obtained after cART-induced HIV suppression between 1996 and 2009. The outcome was nonaccidental death, with follow-up until 2014. We used Cox proportional hazards models to test whether biomarker concentrations predict time from HIV suppression to death and adjusted for multiple tests. Exploratory factor analysis (EFA) was employed to identify groupings of biomarkers that predict mortality risk. RESULTS: Of 670 men followed up from HIV suppression, 54 died by the end of 2013. After adjustment for age, CD4(+) cell count, hepatitis B or C virus infection, and smoking, concentrations in the highest quartile of 4 biomarkers were significantly associated with mortality risk after controlling the false discovery rate at 5%: interleukin (IL) 6 (hazard ratio, 3.54; 95% confidence interval, 2.06-6.10), soluble IL 2Rα (3.29, 1.85-5.85), soluble CD14 (2.67, 1.55-4.61), and chemokine (CXC motif) ligand 13 (CXCL13; 2.26; 1.29-3.95). EFA yielded 2 biomarker groupings that were independent predictors of mortality risk. CONCLUSIONS: Despite having undetectable HIV RNA levels during cART, men with higher concentrations of several biomarkers (particularly IL 6, soluble IL 2Rα, soluble CD14, and CXCL13) had higher hazards of long-term mortality. Correlations observed among biomarker concentrations may represent underlying inflammatory processes that contribute to mortality risk.
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Phyllis C Tien; Andy I Choi; Andrew R Zolopa; Constance Benson; Russell Tracy; Rebecca Scherzer; Peter Bacchetti; Michael Shlipak; Carl Grunfeld Journal: J Acquir Immune Defic Syndr Date: 2010-11 Impact factor: 3.731
Authors: Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay Journal: J Infect Dis Date: 2014-05-01 Impact factor: 5.226
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Laura Visconti; Katherine Nelissen; Laura Deckx; Marjan van den Akker; Wim Adriaensen; Liesbeth Daniels; Cathy Matheï; Loes Linsen; Niels Hellings; Piet Stinissen; Frank Buntinx Journal: Biomark Med Date: 2014 Impact factor: 2.851
Authors: Chad J Achenbach; Ashley L Buchanan; Stephen R Cole; Lifang Hou; Michael J Mugavero; Heidi M Crane; Richard D Moore; Richard H Haubrich; Satish Gopal; Joseph J Eron; Peter W Hunt; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata Journal: Clin Infect Dis Date: 2014-02-12 Impact factor: 9.079
Authors: Bruno Bezerril Andrade; Katherine Huppler Hullsiek; David R Boulware; Adam Rupert; Martyn A French; Kiat Ruxrungtham; Marisa Luisa Montes; Huw Price; Pablo Barreiro; Jennifer Audsley; Alan Sher; Sharon R Lewin; Irini Sereti Journal: J Infect Dis Date: 2013-01-18 Impact factor: 5.226
Authors: Bernard J Macatangay; Ming Yang; Xin Sun; Jessica Morton; Victor De Gruttola; Susan Little; Christine Hogan; Charles R Rinaldo Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Konstantia Angelidou; Peter W Hunt; Alan L Landay; Cara C Wilson; Benigno Rodriguez; Steven G Deeks; Ronald J Bosch; Michael M Lederman Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Rachel Lena Rutishauser; Wendy Hartogensis; Christian Deo Deguit; Melissa Krone; Rebecca Hoh; Frederick M Hecht; Christopher D Pilcher; Peter Bacchetti; Steven G Deeks; Peter W Hunt; Joseph M McCune Journal: AIDS Res Hum Retroviruses Date: 2017-04-25 Impact factor: 2.205
Authors: Haidong Lu; Pamela J Surkan; Michael R Irwin; Glenn J Treisman; Elizabeth C Breen; Ned Sacktor; Ron Stall; Steven M Wolinsky; Lisa P Jacobson; Alison G Abraham Journal: Am J Epidemiol Date: 2019-11-01 Impact factor: 4.897
Authors: Julie B Dumond; Camden P Bay; Julie A E Nelson; Angel Davalos; Andrew Edmonds; Kristina De Paris; Craig Sykes; Kathryn Anastos; Roopali Sharma; Seble Kassaye; Bani Tamraz; Audrey L French; Stephen Gange; Ighovwerha Ofotokun; Margaret A Fischl; David E Vance; Adaora A Adimora Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: Martin Krsak; Nikolas I Wada; Michael W Plankey; Gregory L Kinney; Marta Epeldegui; Chukwuemeka N Okafor; Mackey Reuel Friedman; Frank J Palella; Kristine M Erlandson Journal: Cannabis Cannabinoid Res Date: 2021-04-15
Authors: Long Zhang; Todd T Brown; Joseph B Margolick; Mallory D Witt; Frank J Palella; Lawrence A Kingsley; Andrew N Hoofnagle; Adrienne Tin; Lisa P Jacobson; Alison G Abraham Journal: AIDS Res Hum Retroviruses Date: 2018-10-30 Impact factor: 2.205